AstraZeneca India gets CDSCO nod for Fasenra in rare hypereosinophilic syndrome
The approval expands the drug's use beyond severe asthma, but the patient pool for this rare disease is small. Financial impact is likely modest relative to recent oncology wins.
— 4 earlier stories on Astrazeneca Pharma India Ltd. →What's new
- CDSCO approved Fasenra (benralizumab) for hypereosinophilic syndrome in patients 12 and older.
- The drug was already approved in India for severe eosinophilic asthma.
- Approval dated July 15, 2026; launch subject to further statutory approvals.
Why this matters
AstraZeneca India adds a rare-disease indication to its portfolio, but with a limited patient population the revenue upside is modest. The approval is a genuine regulatory milestone yet smaller than recent oncology launches like Enhertu.
What we're watching
- Timing of commercial launch after remaining statutory approvals.
- Initial prescription trends and patient uptake.
- Any pricing or access hurdles given the niche indication.
The full read
AstraZeneca Pharma India added another arrow to its specialty quiver. The CDSCO approved Fasenra (benralizumab) for hypereosinophilic syndrome (HES) in patients aged 12 years and older, an expansion from its existing use in severe eosinophilic asthma. The 30 mg/ml injection depletes eosinophils, a mechanism proven in asthma now applied to a rare disorder. But rare is the operative word. Unlike the company's recent oncology wins (Enhertu generated over $3 billion globally last year), HES addresses a small patient population. The July 15, 2026 approval is a genuine regulatory milestone and warrants model revisions, but the revenue lift will be modest. For a company that grew FY26 revenue 33% to ₹22.8 billion on oncology launches, this is a quiet step forward, not a game changer.
Questions answered
- What is hypereosinophilic syndrome (HES)?
- HES is a rare disorder characterised by persistently high eosinophil counts that can damage organs. It occurs in patients without an identifiable non-haematologic secondary cause.
- How does Fasenra work in HES?
- Fasenra (benralizumab) depletes eosinophils by binding to the IL-5 receptor alpha subunit, reducing eosinophil-mediated inflammation. It is administered as a 30 mg/ml solution via pre-filled syringe.
- How large is the HES patient population in India?
- The analyst rationale describes HES as a rare disease with a limited patient population. No specific number is provided, but it is expected to be small compared to conditions like asthma.
- What does this approval mean for AstraZeneca India's revenue?
- The analyst notes a modest boost to revenue forecasts. Given the small patient pool, the financial impact is smaller than the company's recent oncology indication wins, such as Enhertu.
- When will Fasenra be available for HES patients in India?
- The approval is dated July 15, 2026, but launch is subject to related statutory approvals beyond the CDSCO permission. The company has not given a specific launch date.
- How does this compare to AstraZeneca's recent Enhertu approval?
- Enhertu had global sales exceeding $3 billion last financial year and targets a much larger breast cancer population. The HES approval targets a rare disease with far lower revenue potential.
Astrazeneca Pharma India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ASTRAZEN →- 16 Jul 2026 · 2:27 PM IST AstraZeneca India gets CDSCO nod for Fasenra in rare hypereosinophilic syndrome
- 35d ago AstraZeneca India gets Enhertu nod for first-line HER2 breast cancer
- 51d ago AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
- 51d ago AstraZeneca Pharma India profit rises to ₹1.9 billion
- 56d ago AstraZeneca India wins CDSCO nod for Calquence in MCL